Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TYLENOL vs Artemether-Lumefantrine
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen is a centrally acting analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, preferentially COX-2, and modulation of descending serotonergic pathways.
Artemether is rapidly converted to dihydroartemisinin, which produces free radicals that damage parasite proteins and membranes. Lumefantrine inhibits heme detoxification in the parasite food vacuole.
Mild to moderate pain (FDA-approved),Fever (FDA-approved),Osteoarthritis pain (off-label),Patent ductus arteriosus in neonates (off-label IV formulation)
Treatment of uncomplicated malaria due to Plasmodium falciparum,Treatment of chloroquine-resistant malaria
650 mg orally every 4-6 hours or 1000 mg orally every 6 hours; maximum 4000 mg per day.
Oral, 4 tablets (each containing 20 mg artemether and 120 mg lumefantrine) at 0, 8, 24, 36, 48, and 60 hours (total 6 doses). For patients ≥35 kg, alternatively 4 tablets at 0, 8, 24, 36, 48, and 60 hours.
Terminal elimination half-life is 2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment
Artemether: terminal elimination half-life approximately 1–2 hours. Dihydroartemisinin: approximately 1–2 hours. Lumefantrine: terminal elimination half-life 4–5 days (range 2–6 days) in patients with uncomplicated malaria; prolonged half-life contributes to post-treatment prophylaxis but may lead to accumulation with repeated dosing.
Primarily hepatic via conjugation with glucuronide (UGT1A1, UGT1A6, UGT1A9) and sulfate (SULT1A1, SULT1A3); minor oxidation by CYP2E1, CYP1A2, and CYP3A4 to N-acetyl-p-benzoquinone imine (NAPQI), which is detoxified by glutathione.
Artemether is metabolized by CYP3A4 to dihydroartemisinin. Lumefantrine is metabolized by CYP3A4.
Renal excretion of conjugated metabolites (glucuronide and sulfate conjugates) accounts for >90% of elimination; less than 5% excreted unchanged; minor biliary/fecal elimination (<5%)
Primarily fecal (biliary) elimination of unchanged drug and metabolites; renal excretion is negligible (<1% for artemether and <0.1% for lumefantrine). Artemether is extensively metabolized by CYP3A4/5 to dihydroartemisinin, which is further glucuronidated and excreted in bile. Lumefantrine is metabolized by CYP3A4 to desbutyl-lumefantrine; both parent and metabolite are eliminated via feces.
10-25% bound to plasma proteins (primarily albumin); binding is minimal and not clinically significant
Artemether: 95% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Dihydroartemisinin: 93% bound. Lumefantrine: >99% bound to high-density lipoproteins (HDL) and, to a lesser extent, to albumin and α1-acid glycoprotein.
0.8-1.0 L/kg; low Vd indicates limited extravascular distribution, consistent with limited CNS penetration
Artemether: Vd approximately 2–5 L/kg, indicating extensive tissue distribution. Dihydroartemisinin: Vd 0.5–1.5 L/kg. Lumefantrine: Vd extremely large, ranging from 10–30 L/kg (reported up to 31 L/kg), reflecting extensive tissue binding and accumulation in erythrocytes and organs (liver, lung, kidney).
Oral: 60-90% (first-pass hepatic metabolism reduces bioavailability); Rectal: 70-90%; Intravenous: 100%
Oral bioavailability: Artemether is 30–40% due to extensive first-pass metabolism by CYP3A4/5 to dihydroartemisinin, which has 80% oral bioavailability. Lumefantrine has highly variable and food-dependent bioavailability; absorption increases 2–16 fold when taken with a high-fat meal. Bioavailability is approximately 5–10% in the fasted state and up to 85% when administered with fat-containing food. The combination is formulated to enhance lumefantrine absorption with a fixed ratio of artemether:lumefantrine 1:6.
GFR 10-50 m L/min: Administer every 6 hours. GFR <10 m L/min: Administer every 8 hours.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%; maximum 2000 mg/day. Child-Pugh C: Reduce dose by 75%; maximum 1000 mg/day.
No dose adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); avoid use.
10-15 mg/kg orally every 4-6 hours; maximum 75 mg/kg/day or 5 doses per day.
Weight-based dosing: 5-<15 kg: 1 tablet per dose; 15-<25 kg: 2 tablets per dose; 25-<35 kg: 3 tablets per dose; ≥35 kg: 4 tablets per dose. Administer at 0, 8, 24, 36, 48, and 60 hours. Crush tablets if needed for children <5 kg.
Reduce dose by 25-50% in frail elderly; maximum 3000 mg/day due to increased hepatotoxicity risk.
No specific dose adjustment required. Monitor for QT prolongation and electrolyte disturbances due to potential age-related decline in cardiac conduction.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen in doses exceeding 4000 mg per day. The risk of acute liver failure may be higher in individuals with underlying liver disease and in those who consume alcohol chronically.
None
Hepatotoxicity: Risk increases with doses > 4000 mg/day, chronic alcohol use, or preexisting liver disease.,Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis.,Hypersensitivity: Rare anaphylaxis.
QT interval prolongation,Arrhythmias,Recrudescence of infection,Hypersensitivity reactions,Use in hepatic impairment
Hypersensitivity to acetaminophen,Severe hepatic impairment (e.g., active liver disease)
Hypersensitivity to artemether or lumefantrine,Severe malaria,Pregnancy (first trimester) unless no other option
No significant food interactions. Alcohol consumption increases risk of hepatotoxicity; avoid concurrent use. High-carbohydrate meals may slightly delay absorption.
High-fat meal increases absorption; grapefruit juice may increase lumefantrine levels; avoid concurrent use.
Acetaminophen crosses the placenta. First trimester: no increased risk of major malformations in prospective studies; retrospective studies show possible association with gastroschisis and neural tube defects but confounding by indication is likely. Second and third trimesters: no consistent evidence of adverse fetal effects; chronic high doses may cause maternal hepatotoxicity with secondary fetal effects. Avoid prolonged high-dose therapy.
FDA Pregnancy Category C. Artemether-lumefantrine is not recommended in the first trimester unless no alternative; animal studies show embryotoxicity at high doses. Second and third trimester: limited human data but appears safe; no increased risk of congenital malformations reported. Use only if benefit outweighs risk.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio approximately 0.9; peak milk concentration 10-15 µg/m L after 1g oral dose). Relative infant dose is <2% of maternal weight-adjusted dose. Considered compatible with breastfeeding; monitor infant for rash or drowsiness.
Both artemether and lumefantrine are excreted in breast milk in low amounts. M/P ratio: artemether ~0.3, lumefantrine ~0.5. Considered compatible with breastfeeding; no adverse effects observed in infants. Use caution if infant has G6PD deficiency due to theoretical risk of hemolysis.
Increased clearance in pregnancy may reduce AUC by 25-30%; recommend standard dosing (500-1000mg every 4-6 hours, max 3000-4000mg/day). No dosage adjustment typically needed. Avoid extended-release formulations due to variable absorption.
No dose adjustment required for uncomplicated malaria in second and third trimester. First trimester: avoid unless no alternative; use same weight-based dosing. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) do not mandate dose changes; standard 6-dose regimen over 3 days is recommended.
Acetaminophen has minimal anti-inflammatory effect; prefer NSAIDs for inflammation. Max daily dose 3 g (or 2 g in at-risk patients). N-acetylcysteine is antidote for overdose; administer if serum level above nomogram line. Avoid in severe hepatic impairment. Intravenous formulation available for acute pain. Onset of action 30-60 min, duration 4-6 h. No effect on platelets or GI mucosa.
Monitor ECG for QTc prolongation; administer with fatty food to enhance absorption; avoid in patients with severe hepatic impairment; pregnancy category C; caution with CYP3A4 inhibitors or inducers.
Do not exceed 3 g (3000 mg) per day from all products.,Check all over-the-counter medications for acetaminophen content.,Do not take with alcohol or if you have liver disease.,Seek immediate medical attention if overdose is suspected.,May be taken with food if GI upset occurs (though rare).
Take with a high-fat meal or whole milk to improve absorption.,Complete the full 3-day course even if symptoms improve.,Seek medical attention for signs of severe malaria (e.g., altered consciousness, difficulty breathing).,Avoid grapefruit juice during treatment.,Use effective contraception if of childbearing potential.
No interactions on record
"Anagrelide, a phosphodiesterase 3 (PDE3) inhibitor used for thrombocythemia, and artemether, an antimalarial artemisinin derivative, both prolong the QT interval by inhibiting cardiac potassium channels (specifically IKr). Concurrent use may result in additive QTc prolongation, increasing the risk of Torsade de Pointes and other ventricular arrhythmias. This risk is particularly relevant in patients with electrolyte imbalances, bradycardia, or pre-existing cardiac disease."
"Acepromazine, a phenothiazine antipsychotic/antiemetic, inhibits cytochrome P450 3A4 (CYP3A4), the primary enzyme responsible for metabolizing the antimalarial artemether. Concomitant administration can lead to significantly reduced clearance of artemether, elevating its plasma concentrations. This may increase the risk of dose-dependent toxicities, including neurotoxicity (e.g., ataxia, seizures) and cardiotoxicity (e.g., QT prolongation)."
"Concomitant administration of thioridazine, a potent CYP2D6 inhibitor, with artemether, a substrate of CYP2D6, can significantly increase the serum concentration of artemether. This elevation may potentiate the antimalarial effect but also heightens the risk of artemether-related adverse effects such as QT prolongation and neurotoxicity. Clinically, this interaction warrants caution due to potential cardiotoxicity and altered drug exposure."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TYLENOL vs Artemether-Lumefantrine, answered by our medical review team.
TYLENOL is a Analgesic (non-opioid) that works by Acetaminophen is a centrally acting analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, preferentially COX-2, and modulation of descending serotonergic pathways.. Artemether-Lumefantrine is a Antimalarial that works by Artemether is rapidly converted to dihydroartemisinin, which produces free radicals that damage parasite proteins and membranes. Lumefantrine inhibits heme detoxification in the parasite food vacuole.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TYLENOL and Artemether-Lumefantrine depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TYLENOL is: 650 mg orally every 4-6 hours or 1000 mg orally every 6 hours; maximum 4000 mg per day.. The standard adult dose of Artemether-Lumefantrine is: Oral, 4 tablets (each containing 20 mg artemether and 120 mg lumefantrine) at 0, 8, 24, 36, 48, and 60 hours (total 6 doses). For patients ≥35 kg, alternatively 4 tablets at 0, 8, 24, 36, 48, and 60 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TYLENOL and Artemether-Lumefantrine in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TYLENOL is classified as Category C. Acetaminophen crosses the placenta. First trimester: no increased risk of major malformations in prospective studies; retrospective studies show possible association with gastrosch. Artemether-Lumefantrine is classified as Category C. FDA Pregnancy Category C. Artemether-lumefantrine is not recommended in the first trimester unless no alternative; animal studies show embryotoxicity at high doses. Second and thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.